The ECFS-CTN cannot guarantee that the information provided here is comprehensive. Please go to the ClinicalTrials.gov link for detailed and up-to-date information on study background, eligibility criteria, study design, outcome measures, study status, participating sites, sponsor contact information and timelines.
You can also contact the CTN coordinating centre for additional information: ECFS-CTN@uzleuven.be (link sends e-mail)
| Study Name on ClinicalTrials.gov (link is external) | Study of Ivacaftor in Cystic Fibrosis Subjects 2 Through 5 Years of Age With a CTFR Gating Mutation |
|---|---|
| Study Drug | Ivacaftor (VX770) |
| Type of Study Drug | CFTR Modulation |
| Study Title | A Phase 3, 2-Part, Open-Label Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are 2 Through 5 Years of Age and Have a CFTR Gating Mutation |
| Study Phase | 3 |
| Study Sponsor | Vertex |
| Participating ECFS-CTN sites | UK: London |
| Age | 2-5 Years |